SRTA Stock: Analyst Targets Suggest +100% Upside to $9.50 for Strata Critical Medical

Key Takeaways

• The central stock price target of $9.50 is the rounded arithmetic mean of four current analyst price targets, which average roughly $9.56.
• The analyst range is wide, from $8.00 to $12.75, with a consensus "Strong Buy" rating.
• With shares near $4.72, reaching $9.50 would require upside of roughly 100%, a very large move.
• Supportive factors include the Keystone Perfusion Services acquisition, organ-transplant logistics demand, and 2026 revenue guidance of $255 million to $270 million.
• Key risks: the company is still unprofitable, trades at a high multiple of revenue, and faces acquisition-integration and execution risk.
• Get more context on the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
• Explore Trending AI Robots to see AI-driven trading strategies applied across the market.

Analyst Price Targets and Consensus View

Strata Critical Medical, Inc. (SRTA) is a small-cap healthcare company focused on time-critical logistics and medical services, including organ transport and transplant clinical support. It was formerly known as Blade Air Mobility and changed its name and ticker in August 2025 after divesting its passenger operations to Joby Aviation. Four sell-side analysts currently provide price targets on the stock, and the average comes to about $9.56, which I round to a central target of $9.50. The individual targets range widely from $8.00 to $12.75, and coverage remains uniformly bullish. Craig-Hallum and B. Riley both started with Buy ratings and $8.00 targets in March 2026, Lake Street has kept a Buy rating with targets in the $8.00-to-$9.50 zone, and Ladenburg Thalmann holds the highest objective near $12.75 after multiple increases through 2026. The reasoning is consistent across firms, centering on the company’s position in organ-transplant logistics, the $124 million Keystone Perfusion Services acquisition funded by its cash reserves, and management’s 2026 revenue guidance of $255 million to $270 million. Differences in targets mainly reflect varying assumptions on margin expansion, integration success, and the timeline to sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Shares trade near $4.72, giving the company a market capitalization of roughly $418 million. From that level, reaching the $9.50 central target would require an increase of approximately 100%, which is a very large move over a 12-month research horizon. The path would need to be supported by fundamentals rather than valuation alone. The company is expanding revenue quickly and has reaffirmed its fiscal 2026 guidance, yet it remains unprofitable with negative EPS over the trailing twelve months. Because the stock lacks a meaningful P/E anchor today, investor support hinges on showing that the combined logistics and clinical businesses can scale margins and turn cash-flow positive, which is exactly what the higher analyst targets assume.

What Could Support a Move Toward the Target

• Organ-transplant logistics demand: Time-critical transport of organs, transplant teams, and medical materials is a structurally growing niche with limited direct competition.
• Keystone Perfusion Services acquisition: The deal expands clinical-service reach and gives management a clear use for its cash, a point analysts have repeatedly cited when raising targets.
• Revenue growth and guidance: Guidance for 2026 revenue of $255 million to $270 million implies double-digit growth and supports a constructive market outlook.
• Cash position and balance sheet: A strong cash balance reduces near-term financing risk while the business works toward profitability.

What Could Prevent the Target From Being Reached

• Persistent losses: The company is not yet profitable, so the valuation relies on future execution that is not guaranteed.
• Valuation compression: A high multiple of revenue leaves limited room for error if growth or margins disappoint.
• Integration risk: Absorbing Keystone and scaling clinical services could prove slower or costlier than modeled.
• Small-cap volatility: With a beta near 1.9 and a limited float, the shares can swing sharply on modest news or sentiment shifts.

Technical Levels and Market Structure

Over the past year, the shares have traded in a broad range from roughly $2.55 to about $6.50. The $6.50 area represents a meaningful resistance level, as it marks the prior 52-week high and sits roughly 38% above the current price. Below, the $4.00 level has acted as a support zone. Reaching $9.50 would require not only breaking above the prior high near $6.50 but extending well beyond it, meaning the stock would need to establish new all-time-high territory on sustained buying interest.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though firms may update them at any time. Investors should monitor quarterly results and the November earnings report, progress on integrating Keystone, updates to full-year guidance, and any analyst target revisions following earnings. For a stock valued primarily on future growth, the most important signals are revenue momentum, gross-margin trends, and the path toward profitability rather than short-term price movement. From what I see, this is important because execution will ultimately determine whether the targets hold.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

I often use Tickeron’s AI Daily Buy/Sell Signals as part of my routine to monitor stocks like this one. The tool applies artificial intelligence to track thousands of equities and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical patterns. It helps me spot changes in trend more efficiently than manual reviews alone, especially when following names with wide analyst target ranges and upcoming catalysts.

Final Assessment

The question of whether SRTA can reach $9.50 is best understood as a test of execution rather than valuation. The central target is the rounded mean of four analyst targets that average about $9.56, within a wide $8.00-to-$12.75 range, and it implies roughly a 100% move from the current price near $4.72. The bull case rests on organ-transplant logistics demand, the Keystone acquisition, and strong revenue guidance, while the bear case centers on continued losses, a rich revenue multiple, and integration risk. Analyst agreement on the "Strong Buy" rating is broad, but the wide spread between the low and high targets signals genuine uncertainty about how quickly margins will improve. Investors should focus next on earnings, guidance, margin progress, and any analyst revisions rather than treating the average target as a promise.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Scott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking

Notable companies

Industry description

Market Cap

High and low price notable news

Volume